Thai FDA approves new treatment for gonorrhoea
Thailand’s Food and Drug Administration has approved Nuzolvence (zoliflodacin), a first-in-class oral antibiotic for the treatment of uncomplicated urogenital gonorrhoea for which Dr. Reddy’s Laboratories with support from The GARDP Foundation had led the priority review submission.Thailand is the second country to approve the new chemical entity. Food and Drug Administration had approved the drug.
- ▪Thailand’s Food and Drug Administration has approved Nuzolvence (zoliflodacin), a first-in-class oral antibiotic for the treatment of uncomplicated urogenital gonorrhoea for which Dr.
- ▪Reddy’s Laboratories with support from The GARDP Foundation had led the priority review submission.Thailand is the second country to approve the new chemical entity.
- ▪Food and Drug Administration had approved the drug.
The Hindu publishes from India and files mainly under world. We currently carry 1,019 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | The Hindu |
| Canonical URL | https://www.thehindu.com/business/thai-fda-approves-new-treatment-for-gonorrhoea/article71273624.ece |
| Publication time | Mon, 27 Jul 2026 23:09:51 +0530 |
| Retrieval time | 2026-07-27T18:12:49.255Z |
| Last seen | 2026-07-27T18:12:49.255Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | qDr6BhUDoHpR · 1 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Thailand’s Food and Drug Administration has approved Nuzolvence (zoliflodacin), a first-in-class oral antibiotic for the treatment of uncomplicated urogenital gonorrhoea for which Dr. Reddy’s Laboratories with support from The GARDP Foundation had led the priority review submission.Thailand is the second country to approve the new chemical entity. Six months ago the U.S. Food and Drug Administration had approved the drug. Zoliflodacin was developed through a public-private partnership involving Innoviva Specialty Therapeutics, a subsidiary of Innoviva Inc.“The approval by the Thai FDA is a significant step in providing timely access to an innovative treatment for gonorrhoea, including infections caused by multidrug-resistant strains,” said Deepak Sapra, CEO–API and Services, Dr.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Hindu.
Discussion
0 commentsMore from The Hindu
